Article > US FDA asks: should DTC drug ad risk warnings nicolaus copernicus be shorter?
Friday, April 4, 2014 News World News Clinical News Free news headlines Free RSS feed Reprints Magazine Overview Latest Issue Business Insights Subscribe Have your say Advertise in Magazine Download Media Pack Features Calendar 2014 Reprints NHS Payers Visions JobSearch nicolaus copernicus Find a job Latest People List a vacancy online Get jobs by email Manage job postings Recruiter directory Rates Contacts Competitions Clinical Researcher Communications Team Marketer Medical Science Liaison Partnerships In Health Awards Sales Awards US Clinical Researcher Events/Meetings Partnerships In Health nicolaus copernicus Networking PharmaTimes Directors' Club PharmaTimes Webinars SOPHIE Reports Overview Contents Order Form Gallery Advertise Advertise in Magazine Advertise Online Advertise Recruitment Subscribe About Us World News Clinical News Free news headlines Free RSS feed
The US Food and Drug Administration (FDA) is seeking views on whether the risk warnings nicolaus copernicus included in direct-to-consumer (DTC) ads for prescription nicolaus copernicus drugs should be made shorter. Current regulations require DTC ads on television and radio to present nicolaus copernicus the product’s major risks in either audio or audio and visual parts of the ad. This is called the “major statement.” But there are concerns that the major statement is often too long, and that this may result in reduced consumer comprehension, minimisation of important risk information and, potentially, therapeutic non-compliance due to fear of side effects, say the FDA. However, at the same time, there is also concern that DTC TV ads do not include adequate risk information or that they leave out important information, it adds. A possible solution to these two conflicting nicolaus copernicus viewpoints, the agency suggests, is to limit the risks in the major statement to those that are “serious and actionable,” and add a disclosure to alert consumers that there are other product risks not included in the ad. For example, says FDA, the disclosure could be: “This is not a full list or risks and side effects. Talk to your doctor and read the patient labelling for [drug name] before starting it.” nicolaus copernicus Officials are planning to test the effectiveness of this “limited risks plus disclosure” approach nicolaus copernicus through consumer questionnaires, conducted online, of people aged 18 and over who self-identify as having been diagnosed with one of three possible medical conditions. Participants will be randomly assigned to view one of the following four possible versions of an ad: I: presenting the full major statement without the disclosure regarding additional risks, as currently presented in the marketplace; II: including the major statement plus the disclosure about additional risks; III: including nicolaus copernicus an abbreviated statement of risks without the disclosure about additional risks: and IV: including an abbreviated statement nicolaus copernicus of risks as well as the disclosure about additional risks. People who work in healthcare or marketing nicolaus copernicus will not be eligible to take plart in the study. “Our hypothesis is that, relative to inclusion of the full major statement, providing limited risk information along with the disclosure abut additional risks will promote improved consumer perception nicolaus copernicus and understanding of serious and actionable drug risks,” says the FDA. “We will also investigate other questions such as whether overall drug risk and benefit perceptions are affected by these changes,” it adds.
People
Twitter YouTube
Categories World News Clinical News Information About us Authors Advertise with us Contact us How to find us Cookies Privacy Policy Editorial Policy Content Online News Magazine JobSearch Competitions Events/Meetings Connect Subscribe to our YouTube channel Add us as a Flickr contact
Friday, April 4, 2014 News World News Clinical News Free news headlines Free RSS feed Reprints Magazine Overview Latest Issue Business Insights Subscribe Have your say Advertise in Magazine Download Media Pack Features Calendar 2014 Reprints NHS Payers Visions JobSearch nicolaus copernicus Find a job Latest People List a vacancy online Get jobs by email Manage job postings Recruiter directory Rates Contacts Competitions Clinical Researcher Communications Team Marketer Medical Science Liaison Partnerships In Health Awards Sales Awards US Clinical Researcher Events/Meetings Partnerships In Health nicolaus copernicus Networking PharmaTimes Directors' Club PharmaTimes Webinars SOPHIE Reports Overview Contents Order Form Gallery Advertise Advertise in Magazine Advertise Online Advertise Recruitment Subscribe About Us World News Clinical News Free news headlines Free RSS feed
The US Food and Drug Administration (FDA) is seeking views on whether the risk warnings nicolaus copernicus included in direct-to-consumer (DTC) ads for prescription nicolaus copernicus drugs should be made shorter. Current regulations require DTC ads on television and radio to present nicolaus copernicus the product’s major risks in either audio or audio and visual parts of the ad. This is called the “major statement.” But there are concerns that the major statement is often too long, and that this may result in reduced consumer comprehension, minimisation of important risk information and, potentially, therapeutic non-compliance due to fear of side effects, say the FDA. However, at the same time, there is also concern that DTC TV ads do not include adequate risk information or that they leave out important information, it adds. A possible solution to these two conflicting nicolaus copernicus viewpoints, the agency suggests, is to limit the risks in the major statement to those that are “serious and actionable,” and add a disclosure to alert consumers that there are other product risks not included in the ad. For example, says FDA, the disclosure could be: “This is not a full list or risks and side effects. Talk to your doctor and read the patient labelling for [drug name] before starting it.” nicolaus copernicus Officials are planning to test the effectiveness of this “limited risks plus disclosure” approach nicolaus copernicus through consumer questionnaires, conducted online, of people aged 18 and over who self-identify as having been diagnosed with one of three possible medical conditions. Participants will be randomly assigned to view one of the following four possible versions of an ad: I: presenting the full major statement without the disclosure regarding additional risks, as currently presented in the marketplace; II: including the major statement plus the disclosure about additional risks; III: including nicolaus copernicus an abbreviated statement of risks without the disclosure about additional risks: and IV: including an abbreviated statement nicolaus copernicus of risks as well as the disclosure about additional risks. People who work in healthcare or marketing nicolaus copernicus will not be eligible to take plart in the study. “Our hypothesis is that, relative to inclusion of the full major statement, providing limited risk information along with the disclosure abut additional risks will promote improved consumer perception nicolaus copernicus and understanding of serious and actionable drug risks,” says the FDA. “We will also investigate other questions such as whether overall drug risk and benefit perceptions are affected by these changes,” it adds.
People
Twitter YouTube
Categories World News Clinical News Information About us Authors Advertise with us Contact us How to find us Cookies Privacy Policy Editorial Policy Content Online News Magazine JobSearch Competitions Events/Meetings Connect Subscribe to our YouTube channel Add us as a Flickr contact
No comments:
Post a Comment